Infrastructure development for human cell therapy translation

Clinical Pharmacology and Therapeutics

Volumn 82, Issue 3, 2007, Pages 320-324

  Dietz, A B ^a   Padley, D J ^a   Gastineau, D A ^a  

^a Mayo Clinic   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

RECOMBINANT DNA;

ASEPSIS; BLOOD BANK; BLOOD CELL; BONE MARROW TRANSPLANTATION; BUILDING; CELL SPECIFICITY; CELL THERAPY; CELL TRANSPLANTATION; CONTROLLED STUDY; DRUG ACTIVITY; GOOD MANUFACTURING PRACTICE; GOOD TISSUE PRACTICE; HUMAN; HUMAN CELL; INFRASTRUCTURE DEVELOPMENT; INSTRUMENT STERILIZATION; INTENSIVE CARE; PRIORITY JOURNAL; PROCESS CONTROL; QUALITY CONTROL; REVIEW;

DRUG INDUSTRY; FACILITY DESIGN AND CONSTRUCTION; HUMANS; STEM CELL TRANSPLANTATION; UNITED STATES; UNITED STATES FOOD AND DRUG ADMINISTRATION;

EID: 34547890682     PISSN: 00099236     EISSN: 15326535     Source Type: Journal    
DOI: 10.1038/sj.clpt.6100288     Document Type: Review

References (19)

1. Rowley, S.D. & Davis, J.M. Standards for bone marrow processing laboratories. Transfusion 30, 571-572 (1990).
2. Bennett, S.T., Johnson, N.L. & Lasky, L.C. Quality assurance and standards in hematopoietic progenitor processing. J. Clin. Apheresis 7, 138-144 (1992).
3. FDA. Public Health Service Act (1999).
4. Malarkey, M. Overview: GMP GTP and QS regulation. in 2nd Annual FDA and the Changing Paradigm for Tissue Regulation 〈http://www.fda.gov/ cber/summaries/tisreg020706mm2.htm〉 (2006).
5. FDA. Tissue related documents 〈http://www.fda.gov.cber/ tissue/docs.htm〉 (2007).
6. FDA. Eligibility determination for donors of human cells, tissues, and cellular and tissue-based products (HCT/Ps) 〈http://www.fda.gov/cber/ gdlns/tissdonor.htm〉 (2007).
7. FDA. Guidance documents 〈http://www.fda.gov/opacom/ morechoices/industry/guidedc.htm〉.
8. FDA. Questions and answers on current good manufacturing practices (cGMP) for drugs 〈http://www.fda.gov/cder/guidance/cGMPs/default. htm〉 (2006).
9. Solomon, R. Regulatory pathways: what regulations apply 〈http://www.fda.gov/cber/tissue/hctpreg012407rs.htm〉 3rd Annual FDA and the Changing Paradigm for HCT/P Regulation, San Antonio, TX (2007).
10. FDA. CBER Homepage 〈http://www.fda.gov/cber/index.html〉.
11. FDA. CDER Homepage 〈http://www.fda.gov/cder/index.html〉.
12. FDA. 21 Code of Federal Regulations Parts 210 and 211 〈http://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfcfr/CFRSearch.cfm? CFRPart=210&showFR=1〉 and 〈http://www.accessdata.fda.gov/scripts/ cdrh/cfdocs/cfcfr/CFRSearch.cfm?CFRPart=211&showFR=1〉 (2006).
13. FDA. Code of Federal Regulations Title 21 - Food and Drugs 〈http://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfcfr/cfrsearch. cfm〉 (2006).
14. FDA. Information on submitting an investigational new drug (IND) application 〈http://www.fda.gov/cber/ind/ind.htm〉 (2007).
15. Crim, J. Facility design and CGMP considerations for cell therapy products. in ISCT 6th Ann. Symp. 〈http://www.fda.gov/cber/ genetherapy/isct092506jcr.htm〉 (2006).
16. Harvath, L. Food and Drug Administration's proposed approach to regulation of hematopoietic stem/progenitor cell products for therapeutic use. Transfus. Med. Rev. 14, 104-111 (2000).
17. FDA. A risk-based approach to pharmaceutical current good manufacturing practices (cGMPs) for the 21st century 〈http://www.fda. gov/cder/gmp/index.htm〉 (2004).
18. Burger, S.R. Design and operation of a current good manufacturing practices cell-engineering laboratory. Cytotherapy 2, 111-122 (2000).
19. McMannis, J.D. & Champlin, R.E. Role of the GMP facility for adoptive immunotherapy. Cytotherapy 4, 329-331 (2002).